Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
ACIU
#6080
AC Immune SA
2.9
3
-0.34%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-0.34%
Aylık değişim
-17.93%
6 aylık değişim
+42.23%
Yıllık değişim
+14.45%
Önceki kapanış
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
Hacim
17
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
ACIU
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
71.94 M
83.48 M
83.62 M
99.2 M
100.41 M
366.71 M
Valuation ratios
Enterprise value
371.91 M
413.22 M
184.8 M
465.24 M
271.11 M
1.33 B
Price to earnings ratio
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
Haberler
AC Immune beyin geçirgen NLRP3 inhibitörü için faz 1 denemesine başladı
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
AC Immune hisseleri olumlu Parkinson hastalığı denemesi verileriyle yükseldi
AC Immune stock rises after positive Parkinson’s disease trial data
AC Immune’un Parkinson tedavisi hastalığın ilerlemesini yavaşlatmada umut veriyor
AC Immune’s Parkinson’s treatment shows promise in slowing disease
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release